ARS Pharmaceuticals, Inc. Common Stock

SPRYNASDAQUSD
9.07 USD
0.33 (3.51%)AT CLOSE (11:59 AM EDT)
9.27
0.20 (2.15%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
9.27
0.20 (2.15%)
🔴Market: CLOSED
Open?$9.40
High?$9.87
Low?$8.96
Prev. Close?$9.40
Volume?2.2M
Avg. Volume?1.9M
VWAP?$9.29
Rel. Volume?1.14x
Bid / Ask
Bid?$9.07 × 100
Ask?$9.45 × 2.3K
Spread?$0.38
Midpoint?$9.26
Valuation & Ratios
Market Cap?900.7M
Shares Out?99.3M
Float?48.2M
Float %?48.8%
P/E Ratio?N/A
P/B Ratio?14.69
EPS?-$1.99
Dividend?0.00%
Ex-Dividend?N/A

ARS Pharmaceuticals, Inc. Common Stock (SPRY) is currently trading at $9.07. SPRY shows a split signal: technical indicators suggest "Buy" while underlying fundamentals indicate "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Furthermore, SPRY is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of May 29, 2026.

News
Profile
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Employees
159
Market Cap
900.7M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2022-11-09
Address
11682 EL CAMINO REAL, SUITE 300
SAN DIEGO, CA 92130
Phone: 858-771-9307
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+1/3)
Medium-Term (Wave)? Bullish(+2/3)
Short-Term (Ripple)? Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
1
Momentum?
50
Short Sent.?
10
Piotroski F-Score?2/9Weak
Altman Z-Score?-0.50Distress
Confidence?63%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?53.72%Squeeze Risk
Short Interest?25.9M
Days to Cover?13.3
Free Float48.2M
Avg Daily Volume1.9M
Settlement Date2026-05-15
Financial Health
Current Ratio?4.94Strong
Quick Ratio?4.77Strong
Cash Ratio?0.49Low
Debt/Equity?2.79High
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A
P/B?
Peers
100
S&P
12
14.69HIGH
P/S?
Peers
100
S&P
9
9.10HIGH
P/FCF?
N/A
EV/EBITDA?
S&P
97
-5.2CHEAP
EV/Sales?
Peers
100
S&P
9
10.58HIGH
Returns & Efficiency
ROE?
S&P
3
-322.5%WEAK
ROA?
S&P
3
-68.8%WEAK
Cash Flow & Enterprise
FCF?$-175318000
Enterprise Value?$1.0B
Fundamentals ratios updated end of day